Ampio Pharmaceuticals Reports the Synergistic Effects of Ampion™ in the Treatment of Osteoarthritis of the Knee in Three Peer-reviewed Publications

ENGLEWOOD, Colo., June 9, 2015 -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion™ in the treatment of osteoarthritis in the knee.

Edward Brody, MD, PhD, Chief Medical Officer Emeritus at Somalogics Inc. and a member of the European Molecular Biology Organization (EMBO) noted, "These first two articles describe research performed by a team of molecular biologists, biochemists and physicians led by Dr. David Bar-Or, Ampio's Chief Science Officer, that has examined the role of Ampion™ in treating chronic pain caused by osteoarthritis of the knee, followed by a review of the literature that explores the inflammatory pathways associated with osteoarthritis of the knee."

Published: 09 June 2015
Written by Editor
AMEX   Up on News   Project Update  
Read more: Ampio Pharmaceuticals Inc ( AMPE )

Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA

TORONTO, May 21, 2015  -- Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA") provided the Company with notification regarding its Investigational New Drug Application ("IND") submission for Rexista(TM) Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets. The notification from the FDA stated that the Company will not be required to conduct Phase III studies if bioequivalence to Oxycontin(TM) is demonstrated.

Published: 21 May 2015
Written by Editor
TSX   Nasdaq   Up on News   Project Update  
Read more: Intellipharmaceutics International ( I / IPCI )

BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%

TORONTO, ONTARIO--(May 13, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its First Quarter (Q1 2015) financial results. Key highlights include:

ImmuCell Announces Results for First Quarter of 2015

Total Sales During First Quarter Increase 49%; Sales of First Defense(R) During First Quarter Increase 62%; Investing in Company-Owned Facility to Meet Growing Sales Demand

PORTLAND, ME--(May 12, 2015) - ImmuCell Corporation (ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its first quarter ended March 31, 2015.

Published: 13 May 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: ImmuCell Corporation ( ICCC )

VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update

VANCOUVER, BRITISH COLUMBIA--(May 4, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(NUVPF) ("VANC" or the "Company") is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy.

Published: 04 May 2015
Written by Editor
FDA HC Decision   Up on News   TSXV  
Read more: VANC Pharmaceuticals Inc ( NPH )
  1. Biostar Pharmaceuticals Inc ( BSPM )
  2. Horizon Pharma plc ( HZNP )
  3. Auspex Pharmaceuticals Inc ( ASPX )
  4. Amarin Corporation Plc ( AMRN )
  5. SciClone Pharmaceuticals Inc ( SCLN )